Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study

References

• Cifu DX, Taylor BC, Carne WF, Bidelspach D, Sayer NA, Scholten J, Campbell EH. Traumatic brain injury, posttraumatic stress disorder, and pain diagnoses in OIF/OEF/OND Veterans. Journal of Rehabilitation Research and Development 2013;50:1169–1176.
   PubMed Web of Science ®Google Scholar
• David X Cifu D-AR, Williams RL, Carne W, West SL, McDougal M, Dixon K. Chronic effects of neurotrauma consortium: An overview at year 1. Federal Practice 2015;32:44–48.
   PubMedGoogle Scholar
• Shively S, Scher AI, Perl DP, Diaz-Arrastia R. Dementia resulting from traumatic brain injury: what is the pathology? Archives of Neurology 2012;69:1245–1251.
   PubMed Web of Science ®Google Scholar
• Shin SS, Dixon CE. Alterations in cholinergic pathways and therapeutic strategies targeting cholinergic system after traumatic brain injury. Journal of Neurotrauma 2015;32:1429–1440.
   PubMed Web of Science ®Google Scholar
• Omalu B, Hammers JL, Bailes J, Hamilton RL, Kamboh MI, Webster G, Fitzsimmons RP. Chronic traumatic encephalopathy in an Iraqi war veteran with posttraumatic stress disorder who committed suicide. Neurosurgical Focus 2011;31:E3.
   PubMed Web of Science ®Google Scholar
• McKee AC, Daneshvar DH, Alvarez VE, Stein TD. The neuropathology of sport. Acta Neuropathologica 2014;127:29–51.
   PubMed Web of Science ®Google Scholar
• McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. Journal of Neuropathology and Experimental Neurology 2009;68:709–735.
   PubMed Web of Science ®Google Scholar
• Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, Wolozin BL, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, McKee AC. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Science Translational Medicine 2012;4:134–160.
   Web of Science ®Google Scholar
• McKee AC, Stern RA, Nowinski CJ, Stein TD, Alvarez VE, Daneshvar DH, Lee HS, Wojtowicz SM, Hall G, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, Wolozin BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013;136:43–64.
   PubMed Web of Science ®Google Scholar
• McKee AC, Robinson ME. Military-related traumatic brain injury and neurodegeneration. Alzheimers & Dementia 2014;10:S242–S253.
   PubMed Web of Science ®Google Scholar
• McKee AC, Stein TD, Kiernan PT, Alvarez VE. The neuropathology of chronic traumatic encephalopathy. Brain Pathology 2015;25:350–364.
   PubMed Web of Science ®Google Scholar
• Daneshvar DH, Goldstein LE, Kiernan PT, Stein TD, McKee AC. Post-traumatic neurodegeneration and chronic traumatic encephalopathy. Molecular and Cellular Neuroscience 2015;66:81–90.
   PubMed Web of Science ®Google Scholar
• Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. The American Journal of Pathology 2011;179:2533–2550.
   PubMed Web of Science ®Google Scholar
• Stein TD, Alvarez VE, McKee AC. Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Research and Therapy 2014;6:4.
   PubMed Web of Science ®Google Scholar
• Mesulam M. Cholinergic aspects of aging and Alzheimer’s disease. Biological Psychiatry 2012;71:760–761.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications. Expert Review of Neurotherapeutics 2008;8:1703–1718.
   PubMedGoogle Scholar
• Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica 2012;123:13–30.
   PubMed Web of Science ®Google Scholar
• Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. Journal of Computational Neurology 1983;214:170–197.
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237–1239.
   PubMed Web of Science ®Google Scholar
• DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology 2002;51:145–155.
   PubMed Web of Science ®Google Scholar
• Arciniegas DB. The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Current Psychiatry Reports 2003;5:391–399.
   PubMedGoogle Scholar
• Murdoch I, Nicoll JA, Graham DI, Dewar D. Nucleus basalis of Meynert pathology in the human brain after fatal head injury. Journal of Neurotrauma 2002;19:279–284.
   PubMed Web of Science ®Google Scholar
• Pike BR, Hamm RJ. Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury. Pharmacology, Biochemistry and Behavior 1997;57:785–791.
   PubMed Web of Science ®Google Scholar
• Donat CK, Walter B, Deuther-Conrad W, Wenzel B, Nieber K, Bauer R, Brust P. Alterations of cholinergic receptors and the vesicular acetylcholine transporter after lateral fluid percussion injury in newborn piglets. Neuropathology and Applied Neurobiology 2010;36:225–236.
   PubMed Web of Science ®Google Scholar
• Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. Progress in Neuropsychopharmacology, Biology and Psychiatry 2005;29:61–67.
   PubMed Web of Science ®Google Scholar
• Masanic CA, Bayley MT, VanReekum R, Simard M. Open-label study of donepezil in traumatic brain injury. Archives of Physical Medicine and Rehabilitation 2001;82:896–901.
   PubMed Web of Science ®Google Scholar
• Walker W, Seel R, Gibellato M, Lew H, Cornis-Pop M, Jena T, Silver T. The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Injury 2004;18:739–750.
   PubMed Web of Science ®Google Scholar
• Kaye NS, Townsend JB, 3rd, Ivins R. An open-label trial of donepezil (aricept) in the treatment of persons with mild traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience 2003;15:383–384; author reply 384–385.
   Google Scholar
• Hefti F. Is Alzheimer disease caused by lack of nerve growth factor? Annals of Neurology 1983;13:109–110.
   PubMed Web of Science ®Google Scholar
• Hefti F, Weiner WJ. Nerve growth factor and Alzheimer’s disease. Annals of Neurology 1986;20:275–281.
   PubMed Web of Science ®Google Scholar
• Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Current Opinions in Neurobiology 2000;10:381–391.
   PubMed Web of Science ®Google Scholar
• Teng KK, Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Molecular Life Sciences 2004;61:35–48.
   PubMed Web of Science ®Google Scholar
• Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E, Braak H. Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathologica 2000;100:259–269.
   PubMed Web of Science ®Google Scholar
• Johnson GVW, Hartigan JA. Tau protein in normal and Alzheimer’s disease brain: An update. Alzheimer’s Disease Review 1998;3:125–141.
   Google Scholar
• Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and the role in neurodegenerative disorders. Brain Researh and Brain Research Reviews 2000;33:95–130.
   PubMed Web of Science ®Google Scholar
• Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Annals of Neurology 2004;55:815–828.
   PubMed Web of Science ®Google Scholar
• Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, Cahill ME, Bigio EH, Berry RW, Binder LI. Tau truncation during neurofibrillary tangle evolution in Alzheimer’s disease. Neurobiology of Aging 2005;26:1015–1022.
   PubMed Web of Science ®Google Scholar
• Ghoshal N, Garcia-Sierra F, Fu Y, Beckett LA, Mufson EJ, Kuret J, Berry RW, Binder LI. Tau-66: evidence for a novel tau conformation in Alzheimer’s disease. Journal of Neurochemistry 2001;77:1372–1385.
   PubMed Web of Science ®Google Scholar
• Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, Binder LI. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer’s disease. Experimental Neurology 2002;177:475–493.
   PubMed Web of Science ®Google Scholar
• Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer’s disease. Journal of Alzheimer’s Disease 2003;5:65–77.
   PubMed Web of Science ®Google Scholar
• Binder LI, Guillozet-Bongaarts AL, Garcia-Sierra F, Berry RW. Tau, tangles, and Alzheimer’s disease. Biochimica et Biophysica Acta 2005;1739:216–223.
   PubMed Web of Science ®Google Scholar
• Guillozet-Bongaarts AL, Cahill ME, Cryns VL, Reynolds MR, Berry RW, Binder LI. Pseudophosphorylation of tau at serine422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. Journal of Neurochemistry 2006;97:1005–1014.
   PubMed Web of Science ®Google Scholar
• Garcia-Sierra F, Ghoshal N, Quinn B, Berry RW, Binder LI. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer’s disease. Journal of Alzheimers Disease 2003;5:65–77.
   PubMed Web of Science ®Google Scholar
• Kanaan NM, Cox K, Alvarez VE, Stein TD, Poncil S, McKee AC. Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy. Journal of Neuropathology and Experimental Neurology 2015;75:19–34.
   Google Scholar
• Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. The Journal of Biological Chemistry 2011;286:23063–23076.
   PubMed Web of Science ®Google Scholar
• Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, Andreadis A, Fu Y, Brady ST, Binder LI. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011;31:9858–9868.
   PubMed Web of Science ®Google Scholar
• McKee AC, Daneshvar DH. The neuropathology of traumatic brain injury. Handbook of Clinical Neurology 2015;127:45–66.
   PubMedGoogle Scholar
• McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, Perl DP, Stein TD, Vonsattel JP, Stewart W, Tripodis Y, Crary JF, Bieniek KF, Dams-O’Connor K, Alvarez VE, Gordon WA, TBI/CTE groupThe first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathologica 2016;131:75–86.
   PubMed Web of Science ®Google Scholar
• Mez J, Solomon TM, Daneshvar DH, Murphy L, Kiernan PT, Montenigro PH, Kriegel J, Abdolmohammadi B, Fry B, Babcock KJ, Adams JW, Bourlas AP, Papadopoulos Z, McHale L, Ardaugh BM, Martin BR, Dixon D, Nowinski CJ, Chaisson C, Alvarez VE, Tripodis Y, Stein TD, Goldstein LE, Katz DI, Kowall NW, Cantu RC, Stern RA, McKee AC. Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Research and Therapy 2015;7:62.
   PubMed Web of Science ®Google Scholar
• Vonsattel JP, Aizawa H, Ge P, DiFiglia M, McKee AC, MacDonald M, Gusella JF, Landwehrmeyer GB, Bird ED, Richardson EP, Jr., Hedley-Whyte ET An improved approach to prepare human brains for research. Journal of Neuropathology and Experimental Neurology 1995;54:42–56.
   PubMed Web of Science ®Google Scholar
• Guillozet-Bongaarts AL, Glajch KE, Libson EG, Cahill ME, Bigio E, Berry RW, Binder LI. Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathologica 2007;113:513–520.
   PubMed Web of Science ®Google Scholar
• Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer’s disease. Proceedings of the National Academy of Science (USA) 2003;100:10032–10037.
   PubMed Web of Science ®Google Scholar
• Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. Journal of Biological Chemistry 2011;286:23063–23076.
   PubMed Web of Science ®Google Scholar
• Ward SM, Himmelstein DS, Lancia JK, Fu Y, Patterson KR, Binder LI. TOC1: characterization of a selective oligomeric tau antibody. Journal of Alzheimers Disease 2013;37:593–602.
   PubMed Web of Science ®Google Scholar
• Kanaan NM, Morfini GA, LaPointe NE, Pigino GF, Patterson KR, Song Y, Andreadis A, Fu Y, Brady ST, Binder LI. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. Journal of Neuroscience 2011;31:9858–9868.
   PubMed Web of Science ®Google Scholar
• Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S. Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer’s disease. Investigative Ophthalmology and Visual Science 2009;50:793–800.
   PubMed Web of Science ®Google Scholar
• Perez SE, Nadeem M, Sadleir KR, Matras J, Kelley CM, Counts SE, Vassar R, Mufson EJ. Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. International Journal of Physiology, Pathophysiology and Pharmacology 2012;4:115–127.
   PubMedGoogle Scholar
• Collins M, Riascos D, Kovalik T, An J, Krupa K, Krupa K, Hood BL, Conrads TP, Renton AE, Traynor BJ, Bowser R. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients. Acta Neuropathologica 2012;124:717–732.
   PubMed Web of Science ®Google Scholar
• Schatteman GC, Gibbs L, Lanahan AA, Claude P, Bothwell M. Expression of NGF receptor in the developing and adult primate central nervous system. Journal of Neuroscience 1988;8:860–873.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Bartus RT, Bothwell M, Schatteman G, Gash DM. Nerve growth factor receptor immunoreactivity in the nonhuman primate (Cebus apella): distribution, morphology, and colocalization with cholinergic enzymes. Journal of Computational Neurology 1988;277:465–486.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer’s disease: a quantitative analysis across subregions of the basal forebrain. Experimental Neurology 1989;105:221–232.
   PubMed Web of Science ®Google Scholar
• Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer’s disease pathology. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 2000;48:1223–1232.
   PubMed Web of Science ®Google Scholar
• Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, Dekosky ST, Klunk WE. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer’s disease. Methods in Enzymology 2006;412:123–144.
   PubMed Web of Science ®Google Scholar
• Hyman BT, Trojanowski JQ Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease from the The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. J Neuropathol Exp Neurol 1997 Oct;56(10):1095–7.
   Google Scholar
• Mufson EJ, Bothwell M, Hersh LB, Kordower JH. Nerve growth factor receptor immunoreactive profiles in the normal, aged human basal forebrain: colocalization with cholinergic neurons. The Journal of Comparative Neurology 1989;285:196–217.
   PubMed Web of Science ®Google Scholar
• Vana L, Kanaan NM, Ugwu IC, Wuu J, Mufson EJ, Binder LI. Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. American Journal of Pathology 2011;179:2533–2550.
   PubMed Web of Science ®Google Scholar
• Mufson EJ, Binder L, Counts SE, DeKosky ST, de Toledo-Morrell L, Ginsberg SD, Ikonomovic MD, Perez SE, Scheff SW. Mild cognitive impairment: pathology and mechanisms. Acta Neuropathologica 2012;123:13–30.
   PubMed Web of Science ®Google Scholar
• Budson AE, Solomon PR. Memory loss, Alzheimer’s disease, and dementia. 2016. Elsevier, St. Louis.
   Google Scholar
• Omalu B, Bailes J, Hamilton RL, Kamboh MI, Hammers J, Case M, Fitzsimmons R. Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. Neurosurgery 2011;69:173–183; discussion 183.
   Google Scholar
• Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. Journal of Neuroscience 2008;28:6926–6937.
   PubMed Web of Science ®Google Scholar
• Ginsberg SD, Mufson EJ, Alldred MJ, Counts SE, Wuu J, Nixon RA, Che S. Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Journal of Chemical Neuroanatomy 2011;42:102–110.
   PubMed Web of Science ®Google Scholar
• Nixon RA, Yang DS. Autophagy failure in Alzheimer’s disease—locating the primary defect. Neurobiology of Disease 2011;43:38–45.
   PubMed Web of Science ®Google Scholar
• Stern RA, Daneshvar DH, Baugh CM, Seichepine DR, Montenigro PH, Riley DO, Fritts NG, Stamm JM, Robbins CA, McHale L, McHale L, Simkin I, Stein TD, Alvarez VE, Goldstein LE, Budson AE, Kowall NW, Nowinski CJ, Cantu RC, McKee AC Clinical presentation of chronic traumatic encephalopathy. Neurology 2013;81:1122–1129.
   PubMed Web of Science ®Google Scholar
• Dewar D, Graham DI. Depletion of choline acetyltransferase activity but preservation of M1 and M2 muscarinic receptor binding sites in temporal cortex following head injury: a preliminary human postmortem study. Journal of Neurotrauma 1996;13:181–187.
   PubMed Web of Science ®Google Scholar
• Murdoch I, Perry EK, Court JA, Graham DI, Dewar D. Cortical cholinergic dysfunction after human head injury. Journal of Neurotrauma 1998;15:295–305.
   PubMed Web of Science ®Google Scholar
• Lopez-Pousa S, Vilalta-Franch J, Garre-Olmo J, Turon-Estrada A, Hernandez-Ferrandiz M, Cruz-Reina ML. [Effectiveness of donepezil at six months in the treatment of cognition deterioration in patients with Alzheimer-type dementia]. Reviews in Neurology 2000;31:724–728.
   PubMed Web of Science ®Google Scholar
• Smith Doody R. Update on Alzheimer drugs (donepezil). Neurologist 2003;9:225–229.
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archives of Internal Medicine 1998;158:1021–1031.
   PubMed Web of Science ®Google Scholar
• Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes K, Williamson D, Zhu Y, Sorra K, Amatniek J. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer’s Disease and Associated Disorders 2008;22:30–38.
   PubMed Web of Science ®Google Scholar
• Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. American Journal of Geriatric Psychiatry 2004;12:420–431.
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Bonanni L, D’Andreamatteo G, Onofrj M. Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clinical Neuropharmacology 2001;24:31–42.
   PubMed Web of Science ®Google Scholar
• Bourgeois JA, Bahadur N, Minjares S. Donepezil for cognitive deficits following traumatic brain injury: a case report. Journal of Neuropsychiatry and Clinical Neurosciences 2002;14:463–464.
   PubMed Web of Science ®Google Scholar
• Trovato M, Slomine B, Pidcock F, Christensen J. The efficacy of donepezil hydrochloride on memory functioning in three adolescents with severe traumatic brain injury. Brain Injury 2006;20:339–343.
   PubMed Web of Science ®Google Scholar
• Stein TD, Montenigro PH, Alvarez VE, Xia W, Crary JF, Tripodis Y, Daneshvar DH, Mez J, Solomon T, Meng G Kubilus CA, Cormier KA, Meng S, Babcock K, Kiernan P, Murphy L, Nowinski CJ, Martin B, Dixon D, Stern RA, Cantu RC, Kowall NW, McKee AC Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathologica 2015;130:21–34.
   PubMed Web of Science ®Google Scholar
• Mesulam MM. Neuroplasticity failure in Alzheimer’s disease: bridging the gap between plaques and tangles. Neuron 1999;24:521–529.
   PubMed Web of Science ®Google Scholar
• King A, Maekawa S, Bodi I, Troakes C, Al-Sarraj S. Ubiquitinated, p62 immunopositive cerebellar cortical neuronal inclusions are evident across the spectrum of TDP-43 proteinopathies but are only rarely additionally immunopositive for phosphorylation-dependent TDP-43. Neuropathology 2011;31:239–249.
   PubMed Web of Science ®Google Scholar
• King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer’s disease. Neuropathology 2010;30:408–419.
   PubMed Web of Science ®Google Scholar